CD4 and prostate carcinoma: (23) observed in 18 patients affected by prostate cancer that during the course of standard RT (70–78 Gy) combined (in 83.3% of the cases) with anti-hormonal therapy, percentage of T cells, CD8+ and naïve CD4+ T cells, and B cells decreased while regulatory T and NK cells increased.